Lantern Pharma (LTRN) Q4 2024 earnings summary

Executive summary

• Advanced three precision oncology programs (LP-300, LP-184, LP-284) with active global enrollment, key milestones, and expansion in East Asia for NSCLC.

• LP-184 received two FDA Fast Track and three Rare Pediatric Disease Designations, enhancing market potential in high-need cancer indications.

• AI-driven RADR® platform surpassed 100 billion oncology data points, accelerating drug development, biomarker discovery, and clinical trial design.

• Starlight Therapeutics subsidiary advanced CNS cancer programs, unveiling STAR-001 trial for recurrent GBM and assembling a world-class advisory board.

• Expanded pipeline to 11 drug programs, including multiple candidates with orphan, fast track, and rare pediatric disease designations.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $24.0 million as of December 31, 2024, down from $41.3 million at year-end 2023, providing at least 12 months of runway.

• Net loss for Q4 2024 was $5.9 million ($0.54/share), up from $4.2 million ($0.39/share) in Q4 2023; full-year net loss was $20.8 million ($1.93/share), compared to $16 million ($1.47/share) in 2023.

• R&D expenses for 2024 were $16.1 million, up from $11.9 million in 2023; G&A expenses were $6.1 million, up slightly from $6 million.

• Operating expenses rose to $22.2 million for 2024, up from $17.9 million in 2023.

• Fully diluted shares outstanding as of December 31, 2024, were approximately 12.1 million.

Outlook and guidance

• Multiple clinical and AI milestones anticipated in 2025, including data readouts from ongoing Phase 1 and 2 programs and public launches of new AI modules.

• Plans to complete LP-184 Phase 1a enrollment and broader data release in Q2 2025, and to begin STAR-001 Phase 1b trial in recurrent GBM, pending funding.

• Expand RADR® platform and pursue additional monetizable collaborations and partnerships.

• Maintain disciplined fiscal management and seek further funding opportunities in 2025.